TL;DR
This study tackles the challenge of imprecision in clinical laboratory tests, specifically how commercial control materials can introduce variability that masks true patient sample behavior. By developing and validating a standardized freezing and thawing protocol, the researchers demonstrate a method to significantly reduce this discrepancy, leading to more reliable quality control and potentially lower laboratory verification costs.
What Problem Does This Paper Address?
Clinical laboratories rely on quality control (QC) materials to monitor the day-to-day imprecision of their analytical systems. However, a critical issue arises when the imprecision observed with these commercial control materials differs from that of actual patient serum samples. This discrepancy, often attributed to the control material's matrix or its processing (storage, reconstitution), can inflate the perceived imprecision of the assay. This makes it harder to accurately detect analytical variations in patient samples, potentially leading to increased verification costs due to false out-of-control results. The paper aims to address this by finding ways to make the imprecision of commercial control materials more "interchangeable" with that of patient serum samples.
Methods
The study employed a three-stage experimental design:
- Stage 1: Screening for Imprecision Differences: Seven common laboratory assays (ASO, C3, CEA, urea, ferritin, total bilirubin, and glucose) were tested using both commercial control materials and patient serum samples with similar concentrations. The imprecision (measured by standard deviation and coefficient of variation) for each analyte was compared. Assays showing a statistically significant difference in imprecision were selected for further investigation.
- Stage 2: Improving Operational Procedures: For the selected assays, a new, standardized processing method was implemented. This involved sealing samples with parafilm, freezing them at -80°C, and thawing them in a water bath. This protocol aimed to minimize variations related to storage and thawing. The imprecision was then re-compared between control materials and serum samples using this new method.
- Stage 3: Verifying Reproducibility: The improvements identified in Stage 2 were incorporated into the laboratory's standard operating procedure. This stage involved analyzing 21 routine assays to confirm that the new method was reproducible and effective across a broader range of analytes.
Statistical analysis involved comparing the standard deviations (SDs) using an F-test or coefficients of variation (CVs) using a modified F-test (H-test) to determine statistical significance (p < 0.05).
Datasets
The study utilized:
- Commercial Control Materials: From Cliniqa Corp. (Liquid QC ImmuTROL Serum Protein Control) and Bio-Rad Laboratories, Inc. (Lyphochek Assayed Chemistry Control, Lyphochek Tumor Marker Plus Control, and Lyphochek Immunoassay Plus Control).
- Patient Serum Samples: Obtained from routine patient samples at the Changsha Kingmed Center for Clinical Laboratory, selected to have concentrations similar to the control materials.
No new benchmark datasets were introduced; the focus was on comparing existing sample types under different processing conditions.
Key Insights and Ideas
- Control Material Processing Matters: The study strongly suggests that the way control materials are stored and thawed significantly impacts their imprecision and their comparability to patient samples.
- -80°C Freezing is Superior for Some Analytes: For certain analytes, particularly glucose, storing samples at -80°C and thawing them in a water bath (as opposed to -20°C and room temperature thawing) dramatically reduced imprecision differences between control materials and serum.
- Standardization is Key: Implementing a strict, standardized protocol for sample handling (freezing, thawing, mixing) is the most effective way to reduce variations introduced by control material processing.
- Reduced Imprecision Enhances QC: By making control material imprecision more interchangeable with serum sample imprecision, laboratories can achieve more informative QC data, better detect analytical system variations, and potentially reduce costly false out-of-control events.
Key Results
- Stage 1: Statistically significant differences in imprecision were found for glucose (Level 1) and total bilirubin (Level 2) between commercial control materials and serum samples. In these cases, control material imprecision was higher.
- Stage 2: The new protocol ("sealed with parafilm, frozen at -80°C, and thawed in water bath") eliminated the statistically significant difference in imprecision for glucose (Level 1) and total bilirubin (Level 2) observed in Stage 1. Glucose imprecision was also lower with this method.
- Stage 3: When applied to 21 routine assays, the standardized protocol resulted in a statistically significant decrease in imprecision for eight assays. Notably, for lactate dehydrogenase 1 (LDH 1) and HDL cholesterol (Level 2), which previously did not meet desirable specifications, the new method brought them within acceptable limits.
Limitations and Future Work
- Limited Sample Size in Stage 2: The comparison experiment for Stage 2 was primarily conducted using glucose analyses due to the difficulty in collecting sufficient serum samples for other analytes.
- Exclusion of Other Standardized Operations: The study did not incorporate all potential standardized operations used in previous research, such as using specific dilution dispensers or water with very low conductivity, due to experimental limitations.
- Future Work: The authors suggest that selecting control materials with inherently interchangeable imprecision with patient samples is ideal. However, if this is not possible, adopting the strict operational control methods described in this study can effectively reduce the impact of control materials, making imprecision across control materials and patient serum samples interchangeable. They also highlight the importance of considering assays with high coefficients of variation and poor interchangeability when selecting control materials.
Summary updated